RARG抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P12095(RARG Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The retinoic acid receptor gamma (RARG) is a member of the nuclear receptor superfamily that regulates gene expression by binding retinoic acid, a derivative of vitamin A. It plays critical roles in cellular differentiation, proliferation, and apoptosis, particularly during embryonic development and tissue homeostasis. RARG is structurally similar to other retinoic acid receptors (RARα and RARβ) but exhibits distinct tissue-specific expression patterns, with high activity in the skin, brain, and certain immune cells.

Antibodies targeting RARG are essential tools in biomedical research, enabling the study of its expression, localization, and functional interactions. They are widely used in techniques like immunohistochemistry, Western blotting, and flow cytometry to investigate RARG's role in health and disease. Dysregulation of RARG has been implicated in cancers (e.g., leukemia, breast cancer), skin disorders, and developmental anomalies. For instance, RARG mutations or altered expression may contribute to chemotherapy resistance in cancer by affecting cell survival pathways.

In recent years, RARG antibodies have also gained attention in toxicology and drug development, as RARG is a key mediator of retinoid signaling and a potential biomarker for adverse drug reactions. Their specificity and reliability are critical for elucidating RARG-related molecular mechanisms and advancing therapeutic strategies targeting retinoid pathways.